Beta test rollout. This site is in community QA — please send feature requests, bug reports and data corrections on the Feedback page or on GitHub.

Home
    Disclaimer
    Tiletamine molecular structure

    Tiletamine Stats & Data

    O-tce Ci-634 Cl-399 Telazol Zoletil
    NPS DataHub
    MW223.34
    FormulaC12H17NOS
    CAS14176-49-9
    IUPAC2-Ethylamino-2-(2-thienyl) cyclohexanone
    SMILESCCNC1(CCCCC1=O)c1cccs1
    InChIKeyQAXBVGVYDCAVLV-UHFFFAOYSA-N
    Arylalkylamines Arylcyclohexylamines
    Chemical Class Arylcyclohexylamine
    Psychoactive Class Depressant / Dissociative

    Pharmacology

    DrugBank

    Description

    This drug is a dissociative anesthetic agent that falls under the drug category of _NMDA receptor antagonists_. Tiletamine is chemically similar to another dissociative anesthetic, ketamine. Tiletamine hydrochloride, the salt form, exists as odorless white crystals.

    Receptor Profile

    Receptor Actions

    Antagonists
    NMDA receptor antagonist (noncompetitive)

    Effect Profile

    Curated + 7 Reports
    Dissociative 5.7

    Strong dissociative depth with strong motor impairment, moderate mania, low insight

    Dissociative Depth×3
    10
    Mania / Compulsion×1
    6
    Insight / Novel Thought×2
    3
    Motor / Sensory Impairment×1
    10
    Based on reports from:

    Tolerance & Pharmacokinetics

    drugs.wiki
    Half-Life
    Not established in humans; limited animal/veterinary literature exists but is not directly translatable to human non-medical use.
    Addiction Potential
    Moderate to high: rapid tolerance with binge liability reported in user communities; some users report compulsive redosing and movement-related adverse effects after multi-day use.

    Tolerance Decay

    Full tolerance 1d Half tolerance 14d Baseline ~28d

    Tolerance to dissociatives can develop rapidly over a single session and decays over ~7–14 days; values reflect anecdotal community observations and general dissociative patterns rather than controlled human data.

    Cross-Tolerances

    ketamine
    PCP analogues (e.g., O-PCE)
    MXE

    Experience Report Analysis

    Erowid
    13 Reports
    7 Single-substance
    1997–2021 Date Range
    7 With Age Data
    2 Effects Detected

    Demographics

    Gender Distribution

    Too few reports for a chart: gender is known from 13 reports, and a split is drawn only from 20 reports or more. Counts are shown instead. Why 20?

    • Male 9 of 13
    • Not Specified 4 of 13

    Age Distribution

    Reports Over Time

    Effect Analysis

    Erowid

    Effects aggregated from 7 experience reports (7 single-substance Erowid)

    7 Reports
    2 Effects Detected
    1 Positive
    0 Adverse
    1 Neutral

    Effect Sentiment Distribution

    Confidence Distribution

    Each bar is the share of reports mentioning the effect; its whisker, and the band on the rows below, is the 95% interval: where the share could plausibly be with other reports of the same kind.

    Too few reports for bars: these effects come from 7 single-substance Erowid reports, and a bar is drawn only from 20 reports or more. With fewer, a percentage cannot tell a common effect from a rare one. Counts are shown instead. Why 20?

    Positive Effects 1

    Euphoria 3 of 7 70%

    Adverse Effects 0

    Show 1 neutral or unclassified mention
    Dissociation 3 of 7

    Also reported in combinations. In the 6 Tiletamine reports where another drug was taken too, 1 mentions hospital, emergency services or an overdose, 0 a seizure and 1 psychosis (too few reports for percentages). In the 7 single-substance reports: 1, 0 and 1. These are not in the figures above: they cannot be put down to Tiletamine alone, and a mention is not always something that happened to the writer.

    Real-World Dose Distribution

    Erowid

    From 7 of 14 recorded dose entries: those that state a weight (mg, g or µg), in routes with at least five of them. Values above Q3 + 3×IQR, far above what people typically take, are left out; they can include real heavy doses and overdoses, not only mistakes.

    Insufflated (n=7)

    Median: 15.0mg 25th: 11.5mg 75th: 22.5mg 90th: 39.0mg

    Common Combinations

    Most co-occurring substances, as a share of all 13 reports filed under Tiletamine

    Too few reports for bars: these combinations come from 13 reports, and a bar is drawn only from 20 reports or more. With fewer, a percentage cannot tell a common effect from a rare one. Counts are shown instead. Why 20?

    • THC 3 of 13
    • Zolazepam 3 of 13

    Form / Preparation

    Most common forms and preparations, as a share of the 10 reports that give one

    Too few reports for bars: these forms come from 10 reports, and a bar is drawn only from 20 reports or more. With fewer, a percentage cannot tell a common effect from a rare one. Counts are shown instead. Why 20?

    • Liquid 4 of 10
    • Powder / Crystals 4 of 10

    Redose Patterns

    Redosing behavior across 10 reports

    2 of 10 Redosed
    1.6 Avg Doses
    150m Median Interval

    Too few reports for a chart: redosing is known from 10 reports, and a split is drawn only from 20 reports or more. Counts are shown instead. Why 20?

    • Single dose 8 of 10
    • Redosed 2 of 10

    Harm Reduction

    drugs.wiki

    Evidence-informed harm reduction points and context: (1) Commercial veterinary products (Telazol/Zoletil) contain equimolar zolazepam with tiletamine. After reconstitution, Telazol solution is strongly acidic (pH ≈2.2–2.8), which helps explain reports of intense nasal burn and potential injection-site irritation; this also means sterile, isotonic preparation and low-volume IM administration reduce local irritation. (2) Clean, pure tiletamine HCl (without zolazepam) has circulated on the grey market; user reports consistently describe substantially higher potency than ketamine by weight and a harsher hangover. (3) Numerous community reports describe coarse tremor, disequilibrium, and lingering neurologic symptoms after repeated dosing over hours–days; spacing sessions and avoiding redosing during the active/offset phase is prudent. (4) Dissociative powders are frequently mis-sold or adulterated; drug checking services routinely find dissociatives sold as other drugs (and vice versa), so reagent tests are insufficient to confirm identity and submitting samples for laboratory GC/MS where available is advised. (5) There is little human pharmacokinetic data for tiletamine; extrapolating animal or vet-product data directly to human non-medical use is unreliable. (6) Reagent reference data for tiletamine are scarce/inconsistent; color tests may be misleading, reinforcing the value of professional analysis. (7) If using any veterinary formulation, account for zolazepam: additive sedation and paradoxical interactions with alcohol and GABAergic drugs are possible and can prolong recovery. (8) As with other dissociatives, avoid combining with CNS depressants (alcohol, opioids, benzos) due to increased risk of loss of airway reflexes, emesis with aspiration, and blackouts.

    References

    Data Sources

    ← Back to Tiletamine